What makes a methodological criticism substantive: it identifies a specific feature of the design that materially affects what the paper can conclude. "Small sample size" alone is weak. "Small sample size for a rare outcome, so the confidence interval is wide" is stronger.
Reverse causation in a cohort study of weight and outcome — a second dataset
post #25 answers the question as asked. The question underneath it is different.
I disagree with the reply above, and I think the disagreement is substantive rather than terminological.
The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient.
Criticise the method, not the author: a paper with a weak design is not a bad paper by someone with bad intentions. It is a paper that answers a limited question. Sometimes that is what the sponsor wanted, sometimes the researchers did the best they could with constraints.
Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own records is not any individual result; it is that they are dated and consecutive.
On post #57 — agreed on the reasoning, with one qualification.
Publication bias: a single published positive trial is weaker evidence than multiple published trials with consistent results. Asking whether there are unpublished negative trials is a fair critical question.
Building consensus on which criticisms matter: if everyone agrees that the sample size is small but only you think that affects the conclusion, maybe your criticism is more idiosyncratic. That does not make it wrong but it is worth noticing.
Bias towards the null and bias away from the null: different criticisms have different directions. Differential dropout might bias away from null; conservative statistical analysis might bias toward null.
I read post #102 twice before replying, because I had assumed the opposite.
Building consensus on which criticisms matter: if everyone agrees that the sample size is small but only you think that affects the conclusion, maybe your criticism is more idiosyncratic. That does not make it wrong but it is worth noticing.
Read the full topic (132 posts)
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
A claim built entirely on a subgroup analysis — what changed since
On the subject in the title: A claim built entirely on a subgroup analysis — what changed since Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…
|
2 | 2k | 18mo | |
|
About the Study critique category
Structured criticism of a specific published study. Criticise the method, not the author. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded with its…
|
4 | 114 | 16mo | |
|
Critiquing an observational claim about a class effect — one year on
Critiquing an observational claim about a class effect — one year on — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a claim…
|
+5 | 9 | 3.2k | 8mo |
|
Selection into a registry and what it does to the estimate — a second dataset
Posting this under the heading it deserves: Selection into a registry and what it does to the estimate — a second dataset Everything below is what sits behind that. Session topic: SURMOUNT-4 ( JAMA , 2024).…
|
+28 | 32 | 1.3k | 1d |
|
Reverse causation in a cohort study of weight and outcome
On the subject in the title: Reverse causation in a cohort study of weight and outcome Working notes rather than a conclusion. Comparing SELECT ( N Engl J Med , 2023) with FLOW ( N Engl J Med , 2024) and…
|
+10 | 14 | 11k | 7mo |
Related topics — sharing the tags risk of bias, observational data, confounding
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
About the Preprints category
Unrefereed work, clearly labelled as such, with the usual caveats stated once and taken seriously. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded…
|
+3 | 7 | 14k | 3mo |
|
About the N-of-1 designs category
Designing a personal experiment that could actually change your mind, including washouts and blinding. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
4 | 22k | 14h | |
|
Blinding yourself: practical methods and their limits — the long version
Blinding yourself: practical methods and their limits — the long version Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURMOUNT-OSA ( N Engl J Med , 2024)…
|
+7 | 11 | 1.8k | 22h |
|
Journal club: STEP 1 and the treatment-policy estimand — does this still hold?
Asking directly, because I could not find a straight answer: Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Comparing STEP 2 ( Lancet , 2021) with SURPASS-2 ( N Engl J Med ,…
|
+70 | 76 | 4.8k | 15h |
|
Journal club: SUSTAIN 6 and its retinopathy signal
On the subject in the title: Journal club: SUSTAIN 6 and its retinopathy signal Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a claim I do not think it…
|
+110 | 122 | 46k | 1d |